These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34863655)

  • 1. CAR Treg: A new approach in the treatment of autoimmune diseases.
    Beheshti SA; Shamsasenjan K; Ahmadi M; Abbasi B
    Int Immunopharmacol; 2022 Jan; 102():108409. PubMed ID: 34863655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.
    Kahmini FR; Shahgaldi S
    Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
    Chen Y; Sun J; Liu H; Yin G; Xie Q
    J Immunol Res; 2019; 2019():5727516. PubMed ID: 32083141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions.
    Ohno R; Nakamura A
    Semin Arthritis Rheum; 2024 Aug; 67():152479. PubMed ID: 38810569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-engineered regulatory T lymphocytes: promise for immunotherapy of autoimmune disease.
    Yi L; Weifan Y; Huan Y
    Cytotherapy; 2019 Sep; 21(9):925-934. PubMed ID: 31105041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg Enhancing Therapies to Treat Autoimmune Diseases.
    Eggenhuizen PJ; Ng BH; Ooi JD
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
    Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
    JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
    Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CARs: a new approach for the treatment of autoimmune diseases.
    Sun Y; Yuan Y; Zhang B; Zhang X
    Sci China Life Sci; 2023 Apr; 66(4):711-728. PubMed ID: 36346550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?
    Santamaria-Alza Y; Vasquez G
    Inflamm Res; 2021 Jun; 70(6):651-663. PubMed ID: 34018005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance.
    Scott DW
    Front Immunol; 2021; 12():742719. PubMed ID: 34552599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy With Regulatory T Cells: A Beneficial Alliance.
    Biswas M; Kumar SRP; Terhorst C; Herzog RW
    Front Immunol; 2018; 9():554. PubMed ID: 29616042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets.
    Wu X; Chen PI; Whitener RL; MacDougall MS; Coykendall VMN; Yan H; Kim YB; Harper W; Pathak S; Iliopoulou BP; Hestor A; Saunders DC; Spears E; Sévigny J; Maahs DM; Basina M; Sharp SA; Gloyn AL; Powers AC; Kim SK; Jensen KP; Meyer EH
    Front Immunol; 2024; 15():1415102. PubMed ID: 39007132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application.
    Henschel P; Landwehr-Kenzel S; Engels N; Schienke A; Kremer J; Riet T; Redel N; Iordanidis K; Saetzler V; John K; Heider M; Hardtke-Wolenski M; Wedemeyer H; Jaeckel E; Noyan F
    J Autoimmun; 2023 Jul; 138():103057. PubMed ID: 37224732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.